Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-12-27

Clinical Trial Update: Evaluation of the Efficacy and Safety of Lubiprostone in Adults With Mixed or Unsubtyped Irritable Bowel Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating lubiprostone for adults with mixed or unsubtyped irritable bowel syndrome was terminated with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LUBIPROSTONE (lubiprostone)

Snippet

Sponsor: Sucampo Pharma Americas, LLC | Conditions: Irritable Bowel Syndrome | Phase 2 | Status: TERMINATED | Results posted: 2019-12-27